ReviewJournal of thoracic disease2020
Novel treatment strategies for early-stage lung cancer: the oncologist's perspective.
Review in Journal of thoracic disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- Health-related quality of life assessment in trials testing tyrosine kinase inhibitors or immune checkpoints inhibitors in early-stage NSCLC.The oncologist · 2025Pooled it
- Efficacy and safety of neoadjuvant immunotherapy plus chemotherapy followed by adjuvant immunotherapy in resectable non-small cell lung cancer: a meta-analysis of phase 3 clinical trials.Frontiers in immunology · 2024Pooled it
- Medicaid Expansion and Overall Mortality Among Individuals With Lung Cancer.The Journal of surgical research · 2026Article
- Article
- Treatment Patterns in Early Stage NSCLC in Asia: Findings From the ELEVATE Study.JTO clinical and research reports · 2026Article
- A Canadian Perspective on Perioperative Systemic Therapy in Resectable Non-Small Cell Lung Cancer.Current oncology (Toronto, Ont.) · 2025Review
- Setting the Benchmark: Patterns of Care and Outcomes for Early-stage Non-small Cell Lung Cancer in Queensland, Australia, 2011-2017.Asia-Pacific journal of clinical oncology · 2025Article
- Surgical outcomes of smoking and nonsmoking women with lung adenocarcinoma.Journal of thoracic disease · 2025Article
- A Systematic Review of AI Performance in Lung Cancer Detection on CT Thorax.Healthcare (Basel, Switzerland) · 2025Review
- Review
- IASLC grading system predicts distant metastases for resected lung adenocarcinoma.Journal of clinical pathology · 2025Article
- Update on Practical Management of Early-Stage Non-Small Cell Lung Cancer (NSCLC): A Report from the Ontario Forum.Current oncology (Toronto, Ont.) · 2024Review
- Real-World Clinical Outcomes of Neoadjuvant Platinum-Based Chemotherapy with Nivolumab in Non-Small Cell Lung Cancer.Journal of clinical medicine · 2024Article
- Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum.Cell reports. Medicine · 2024Article
- Chemosensitizing effect of pentoxifylline in sensitive and multidrug-resistant non-small cell lung cancer cells.Cancer drug resistance (Alhambra, Calif.) · 2024Article
- Analysis of Pain Management after Anatomic VATS Resection in Austrian Thoracic Surgery Units.Journal of clinical medicine · 2023Article
- Economic burden of early-stage non-small-cell lung cancer: an assessment of healthcare resource utilization and medical costs.Journal of comparative effectiveness research · 2023Article
- Targeted EGFR Nanotherapy in Non-Small Cell Lung Cancer.Journal of functional biomaterials · 2023Review
- A review of recent advances in the novel therapeutic targets and immunotherapy for lung cancer.Medical oncology (Northwood, London, England) · 2023Review
- Comparing the Therapeutic Efficacies of Lung Cancer: Network Meta-Analysis Approaches.International journal of environmental research and public health · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Management of early-stage non-small cell lung cancer (NSCLC) consists in multimodal treatment, including surgery, radiotherapy and chemotherapy. The mainstay of treatment is radical surgery. Definitive radiotherapy using stereotactic techniques can provide adequate local disease control, and is the treatment of choice in medically inoperable patients. Most early-stage patients are at significant risk of disease relapse after local treatment. Adjuvant platinum-based chemotherapy has demonstrated to provide an absolute survival benefit of 5% compared to observation. However, unlike advanced/metastatic disease, little progress has been made in the treatment of early-stage NSCLC over the past decade. In recent years, plenty of research has focused on the optimization of adjuvant and neoadjuvant treatment. Several trials with novel drugs, such as targeted agents and immune-checkpoint inhibitors are currently underway, with preliminary positive results. Customization of treatment on patients' characteristics before, and major pathological response after therapy, will further improve survival outcomes in this subset of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.